Tech Company Financing Transactions
Beacon Therapeutics Funding Round
On 6/12/2023, Beacon Therapeutics raised $120 million in investment from Oxford Science Enterprises and Syncona.
Transaction Overview
Company Name
Announced On
6/12/2023
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to progress its pipeline to key value inflection points.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
14193 NW 119th Terrace, Suite #10
Alachua, FL 32615
USA
Alachua, FL 32615
USA
Phone
Website
Email Address
Overview
Beacon Therapeutics is an ophthalmic gene therapy company founded to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. Our established scientific foundation combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two innovative and differentiated preclinical programs for prevalent and rare blinding diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Fellows
Chief Medical Officer
Nadia Waheed
Chief Scientific Officer
Abraham Scaria
Vice President
Eduardo Jacobo
Browse more venture capital transactions:
Prev: 6/12/2023: Proclaim venture capital transaction
Next: 6/12/2023: Anise Health venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs